ConductScience.org, home

Gene · 3062

HCRTR2: hypocretin receptor 2

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. HCRTR2: hypocretin receptor 2. Genes, record 3062. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3062

On this page

Gene

Symbol
HCRTR2
HGNC
Name
hypocretin receptor 2
HGNC
NCBI Gene ID
3062
NCBI Gene
HGNC ID
HGNC:4849
HGNC
Ensembl
ENSG00000137252
NCBI Gene
Aliases
ORXR2, OX2R, OXR2
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
O43614Orexin receptor type 244412Ensembl, GeneID, HGNC

Source UniProt

Patents25

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026062654 A2026-04-1045O43614Espacenet
WO 2026019942 A22026-01-22829O43614Espacenet
WO 2026004642 A2026-01-0262O43614Espacenet
EP 4641201 A22025-10-299075O43614Espacenet
JP 2025529142 A2025-09-041925O43614Espacenet
US 12371689 B22025-07-291925O43614Espacenet
JP 2025517969 A2025-06-129075O43614Espacenet
EP 4311832 A12024-01-314O43614Espacenet
JP 2023156353 A2023-10-2445O43614Espacenet
JP 2023153821 A2023-10-1827O43614Espacenet

1 to 10 of 25

See all 25 patents

Drugs10

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
ALMOREXANTCHEMBL455136Orexin receptor antagonistANTAGONISTChEMBL
DARIDOREXANTCHEMBL4297590Orexin receptor antagonistANTAGONISTChEMBL
DARIDOREXANTCHEMBL4297590Orexin receptor 2 antagonistANTAGONISTChEMBL
DARIDOREXANT HYDROCHLORIDECHEMBL4650216Orexin receptor 2 antagonistANTAGONISTChEMBL
FILOREXANTCHEMBL2107822Orexin receptor antagonistANTAGONISTChEMBL
LEMBOREXANTCHEMBL3545367Orexin receptor 2 antagonistANTAGONISTChEMBL
ORN-0829 HYDRATECHEMBL4650522Orexin receptor antagonistANTAGONISTChEMBL
SB-649868CHEMBL1272307Orexin receptor 2 antagonistANTAGONISTChEMBL
SELTOREXANTCHEMBL3597971Orexin receptor 2 antagonistANTAGONISTChEMBL
SUVOREXANTCHEMBL1083659Orexin receptor antagonistANTAGONISTChEMBL

Trials105

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07573176SELTOREXANTPHASE3ClinicalTrials.gov
NCT07480096LEMBOREXANTPHASE2ClinicalTrials.gov
NCT07417813LEMBOREXANTClinicalTrials.gov
NCT07328594DARIDOREXANTPHASE4ClinicalTrials.gov
NCT07132086DARIDOREXANTClinicalTrials.gov
NCT06981195LEMBOREXANTPHASE2ClinicalTrials.gov
NCT06928766LEMBOREXANTPHASE2ClinicalTrials.gov
NCT06854224SUVOREXANTPHASE2ClinicalTrials.gov
NCT06843187LEMBOREXANTPHASE2ClinicalTrials.gov
NCT06823752LEMBOREXANTPHASE2ClinicalTrials.gov

1 to 10 of 105

See all 105 trials

NIH grants598

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleHCRTR2 papersNewest fiscal year
R01DK107859Genetics of chronotype and impact on metabolic disease52025
T32NS007413Training Program in Neurodevelopmental Disabilities42025
T32DA007237Neurobiology of Addiction Training Program32025
P30DK056341Washington University Nutrition Obesity Research Center22025
R01AG050518Hypocretin/orexin modulation of cognitive correlates of brain aging22025
T32DA007288Drug Abuse Training Program22025
T32GM008425Indiana University Comprehensive Training in Clinical Pharmacology22025
T32GM136640Tri-institutional PhD Program in Chemical Biology22025
T32HL007901Training in Sleep, Circadian, and Respiratory Neurobiology22025
UL1TR001863Yale Clinical and Translational Science Award22025

1 to 10 of 598Source NIH's project files

See all 598 nih grants

Papers901

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Beyond traditional sleeping pills: safety, efficacy and multidisease potential of three approved orexin receptor antagonists.Front Psychiatry202642683191PubTator, text miningPubMed
Research Progress and Future Perspectives of Orexin Receptor Antagonists in Insomnia Therapy.Molecules202642653878PubTator, text miningPubMed
Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Neurol202642636845PubTator, text miningPubMed
Oveporexton: The first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1 (NT1).Drug Discov Ther202642618292PubTator, text miningPubMed
The orexin system as a pharmacological target in inflammation: peripheral mechanisms and safety implications.Front Pharmacol202642609337PubTator, text miningPubMed
Probing chemical space and conformational changes for subtype-selective orexin receptor antagonists.RSC Med Chem202642592024PubTator, text miningPubMed
Recent Advances and Emerging Pharmacotherapeutic Approaches for Central Hypersomnolence Disorders.Clin Pharmacol202642583265PubTator, text miningPubMed
Targeting Orexin 2 Receptors in Idiopathic Hypersomnia and Narcolepsy: A Randomised Phase 1b Proof-Of-Concept Study of Alixorexton.J Sleep Res202642551881PubTator, text miningPubMed
Lateral hypothalamic orexinergic neurons as central mediators of pain modulation and non-pharmacological analgesia.Front Pharmacol202642460012PubTator, text miningPubMed
The orexinergic system in the retina: Expression and physiological impact-A review of the literature.Front Neuroendocrinol202642150720PubTator, text miningPubMed

1 to 10 of 901

See all 901 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/3062

GET https://conductscience.org/api/genes/v1/3062/patents?page=2